Based on a survey of biopharmaceutical executives, payers, patients and investors, The New Health Report 2012 builds upon previous calls for multi-stakeholder collaboration by exploring the often misunderstood element of risk as it relates to biopharmaceutical development and delivery.

Brought to you by Quintiles.

**Attendee badges scanned for this White Paper Showcase will be shared with the Company hosting this offering. If you prefer not to have your badge scanned, please inform the DIA staff member.

Learning Objectives:
Describe stakeholder perceptions of risk—both real and perceived—that demonstrate a significant misalignment among biopharmaceutical stakeholders
Describe stakeholder sentiment on risk mitigation strategies such as pre-competitive alliances and performance agreements between biopharma and payers
Provide insight into which types of data are best suited for assessing a biopharmaceutical product's risk/benefit profile.